Skip to main content
Premium Trial:

Request an Annual Quote

AmeriPath CEO James New to Retire; Lewis Sheiner Scientific advisor to Pharsight; Richard Barker Chairman of Molecular Staging; and Others

NEW YORK, Jan. 21 (GenomeWeb News) - James New, the chairman and CEO of AmeriPath, will retire effective Feb. 1, the company said today. Paul Queally, who is a member of the company's board of directors, has been appointed chairman of the company, and a search for a new CEO will begin.

 

In the meantime, the company will be run by the office of the CEO, including David Redmond, the current Chief Financial Officer, Joseph Sonnier, the president, and Martin Stefanelli, the current COO.

 

AmeriPath is a diagnostics and genomics service provider based in Riviera Beach, Fla. New has been the CEO of the company since it was founded.

 

Queally is also a general partner with Welsh Carson, Anderson & Stowe. 

 


 

Lewis Sheiner has renewed a consulting agreement with Pharsight, a drug development IT firm, the company said today.

 

Under the agreement, Sheiner will be a senior scientific advisor.to the Mountain View, Calif., firm.


 

Richard Barkerhas been appointed executive chairman of the board of directors at Molecular Staging, the New Haven, Conn., company said Jan. 20.

 

Barker has previously served as CEO of Chiron Diagnostics, and prior to that was the general manager at IBM's health care solutions business. He has also served for 13 years as the leader of McKinsey & Company's European pharmaceutical practice.


 

James Meadehas been named vice president of business development at Avalon Pharmaceuticals, and Paul Young has been promoted to vice president of research at the company, the company said.

 

Meade comes to Avalon from Pfizer/Pharmacia, where he worked in global licensing of anti-infective and urology products. He has also worked previously at Bayer, Chiron, and Cetus.

 

Young was most recently senior scientific director of discovery biology at Avalon, and a member of its scientific management committee. Prior to that, he worked as a senior scientist at Human Genome Sciences, and previously, at Bayer and Genentech.


 

Gary Kruppa has been named vice president for Western Operations in the US for Bruker Daltonics, the company said Jan. 15.

 

Kruppa will manage the company's life sciences mass spectrometry applications laboratory in Fremont, Calif., and the sales, support, and service operations in the Western US.

 

Kruppa has been a member of the technical staff at Sandia National Laboratories since 2002. At Sandia, he ran a program that focused on using mass spectrometry to study three-dimensional protein structure. Prior to that, Kruppa worked at Bruker Daltonics as vice president of the FTMS division, between 1998 and 2001, and as an FTMS product manager and applications scientist before that. He has also worked as a research scientist at Ciba-Geigy.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.